Merck Reports a 2% Dip in Q1 Sales to $15.5 Billion Amidst Strategic Growth Moves
Merck & Co. reports a 2% sales drop to $15.5 billion in Q1 2025 but sees a 7% rise in net income and EPS. CEO emphasizes strategic growth and innovation.
Merck News
Merck Reports a 2% Dip in Q1 Sales to $15.5 Billion Amidst Strong Earnings Growth
Merck & Co., Inc. reports a 2% decrease in Q1 sales to $15.5 billion for fiscal 2025, alongside a 7% rise in net income and EPS. CEO Robert M. Davis highlights progress in medicine...
Merck Reports Slight Dip in Q1 Sales to $15.5 Billion Amid Strong Earnings Growth
Merck & Co. reports a 2% sales decline to $15.5 billion in Q1 2025 but sees a 7% increase in net income and EPS. CEO Robert M. Davis emphasizes progress in new medicines and pipeli...
Merck Reports a Slight Dip in Q1 Sales to $15.5 Billion Amidst Strong Earnings Growth
Merck & Co., Inc. reported a 2% decline in Q1 sales to $15.5 billion for fiscal 2025, but showcased a 7% increase in net income and EPS. CEO Robert M. Davis highlighted progress in...
Merck Reports a Slight Dip in Q1 Sales to $15.5 Billion Amidst Growth in Net Income
Merck & Co., Inc. reports a 2% decrease in Q1 sales to $15.5 billion but achieves a 7% growth in net income and EPS. CEO highlights progress in medicines and vaccines, with stock p...
Merck Reports a 2% Dip in Q1 Sales to $15.5 Billion Amidst Strategic Growth Moves
Merck & Co., Inc. announced a 2% year-on-year sales decline to $15.5 billion in Q1 2025, alongside a 7% increase in net income and EPS. CEO Robert M. Davis highlighted strategic gr...
Merck Reports a Slight Dip in Q1 Sales to $15.5 Billion Amidst Strong Earnings Growth
Merck & Co., Inc. announced a 2% decrease in Q1 2025 sales to $15.5 billion, alongside a 7% rise in net income and EPS. CEO Robert M. Davis emphasized strategic progress and pipeli...
Merck & Co. Inc. Secures Exclusive Rights to Hengrui Pharma's Promising Cardiovascular Drug for Up to $1.8 Billion
Merck & Co. Inc. has signed an exclusive agreement with Hengrui Pharma for HRS-5346, a phase 2 cardiovascular drug, involving up to $1.8 billion in payments. The drug targets lipop...
Merck Unveils a $1 Billion Vaccine Manufacturing Powerhouse in North Carolina
Merck & Co Inc. has opened a new $1 billion vaccine manufacturing facility in Durham, North Carolina, as part of its $12 billion investment in the US since 2018, with plans for an ...
